Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease (pages 75–88)
Susanne Bäck, Johan Peränen, Emilia Galli, Päivi Pulkkila, Liina Lonka-Nevalaita, Tuulia Tamminen, Merja H. Voutilainen, Atso Raasmaja, Mart Saarma, Pekka T. Männistö and Raimo K. Tuominen
Article first published online: 14 JAN 2013 | DOI: 10.1002/brb3.117
The neuroprotective effect of cerebral dopamine neurotrophic factor (CDNF) delivered with a recombinant adeno-associated viral (AAV) serotype 2 vector was studied in a rat 6-hydroxydopamine (6-ODHA) model of Parkinson's disease. Delivery of AAV2-CDNF into the striatum gave rise to a long-lasting expression of the protein. When given 2 weeks before 6-OHDA, AAV2-CDNF resulted in a marked decrease in amphetamine-induced ipsilateral rotations and provided partial protection of tyrosine hydroxylase-immunoreactive cells in the rat substantia nigra.